Jazz Pharmaceuticals Reports Third-Quarter Revenue of $1.24 Billion

Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) —— Company raises full year 2026 total revenue guidance —— Ziihera® launched in HER2+ 1L mGEA —— Xywav® revenues grew 12% YoY with 425 net patient adds in 3Q26 —— Closed Actio acquisition, adding ABS-1230 (JZP6…

JAZZ PHARMACEUTICALS OUTLOOK FY REVENUE USD 4,775-4,850 MILLION

Jazz Pharmaceuticals rutscht im dritten Quartal 2026 mit 483.4 Millionen US-Dollar in die Verlustzon

Jazz Pharmaceuticals reported third-quarter 2026 revenue of $1.243 billion, up 10% year over year, and raised its full-year revenue guidance. The company recorded a GAAP net loss of $483.4 million, including acquired in-process research and development expense tied to its Actio acquisition. It also…

Ireland's Jazz Pharmaceuticals Q3 revenue beats; 2026 outlook lifted